Literature DB >> 32579935

Small Molecule Dysregulation of TEAD Lipidation Induces a Dominant-Negative Inhibition of Hippo Pathway Signaling.

Jeffrey K Holden1, James J Crawford2, Cameron L Noland3, Stephen Schmidt4, Jason R Zbieg2, Jennifer A Lacap5, Richard Zang6, Gregory M Miller1, Yue Zhang7, Paul Beroza2, Rohit Reja7, Wendy Lee2, Jeffrey Y K Tom1, Rina Fong3, Micah Steffek4, Saundra Clausen4, Thjis J Hagenbeek8, Taishan Hu9, Zheng Zhou10, Hong C Shen9, Christian N Cunningham11.   

Abstract

The transcriptional enhanced associate domain (TEAD) family of transcription factors serves as the receptors for the downstream effectors of the Hippo pathway, YAP and TAZ, to upregulate the expression of multiple genes involved in cellular proliferation and survival. Recent work identified TEAD S-palmitoylation as critical for protein stability and activity as the lipid tail extends into a hydrophobic core of the protein. Here, we report the identification and characterization of a potent small molecule that binds the TEAD lipid pocket (LP) and disrupts TEAD S-palmitoylation. Using a variety of biochemical, structural, and cellular methods, we uncover that TEAD S-palmitoylation functions as a TEAD homeostatic protein level checkpoint and that dysregulation of this lipidation affects TEAD transcriptional activity in a dominant-negative manner. Furthermore, we demonstrate that targeting the TEAD LP is a promising therapeutic strategy for modulating the Hippo pathway, showing tumor stasis in a mouse xenograft model.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hippo pathway; TEAD; YAP; cancer; lipidation; therapeutic; transcription factor

Mesh:

Substances:

Year:  2020        PMID: 32579935     DOI: 10.1016/j.celrep.2020.107809

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  12 in total

Review 1.  Advances in targeting 'undruggable' transcription factors with small molecules.

Authors:  Matthew J Henley; Angela N Koehler
Journal:  Nat Rev Drug Discov       Date:  2021-05-18       Impact factor: 84.694

2.  YAP1 is essential for malignant mesothelioma tumor maintenance.

Authors:  Loreley Calvet; Odette Dos-Santos; Emmanuel Spanakis; Véronique Jean-Baptiste; Jean-Christophe Le Bail; Armelle Buzy; Pascal Paul; Christophe Henry; Sandrine Valence; Colette Dib; Jack Pollard; Sukhvinder Sidhu; Jürgen Moll; Laurent Debussche; Iris Valtingojer
Journal:  BMC Cancer       Date:  2022-06-10       Impact factor: 4.638

Review 3.  Hippo signalling in the liver: role in development, regeneration and disease.

Authors:  Jacquelyn O Russell; Fernando D Camargo
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-01-21       Impact factor: 73.082

Review 4.  Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery.

Authors:  Qingxin Li; CongBao Kang
Journal:  Int J Mol Sci       Date:  2020-07-24       Impact factor: 5.923

5.  Discovery of Covalent Inhibitors Targeting the Transcriptional Enhanced Associate Domain Central Pocket.

Authors:  Hacer Karatas; Mohammad Akbarzadeh; Hélène Adihou; Gernot Hahne; Ajaybabu V Pobbati; Elizabeth Yihui Ng; Stéphanie M Guéret; Sonja Sievers; Axel Pahl; Malte Metz; Sarah Zinken; Lara Dötsch; Christine Nowak; Sasikala Thavam; Alexandra Friese; CongBao Kang; Wanjin Hong; Herbert Waldmann
Journal:  J Med Chem       Date:  2020-10-01       Impact factor: 7.446

Review 6.  Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine.

Authors:  Evan R Barry; Vladimir Simov; Iris Valtingojer; Olivier Venier
Journal:  Cells       Date:  2021-10-11       Impact factor: 6.600

Review 7.  Insights into auto-S-fatty acylation: targets, druggability, and inhibitors.

Authors:  Lu Hu; Zhipeng Tao; Xu Wu
Journal:  RSC Chem Biol       Date:  2021-08-25

Review 8.  Lipid-induced S-palmitoylation as a Vital Regulator of Cell Signaling and Disease Development.

Authors:  Mengyuan Qu; Xuan Zhou; Xiaotong Wang; Honggang Li
Journal:  Int J Biol Sci       Date:  2021-10-11       Impact factor: 6.580

9.  Fisetin Inhibits Osteogenic Differentiation of Mesenchymal Stem Cells via the Inhibition of YAP.

Authors:  Chanchao Lorthongpanich; Thanapon Charoenwongpaiboon; Prapasri Supakun; Methus Klaewkla; Pakpoom Kheolamai; Surapol Issaragrisil
Journal:  Antioxidants (Basel)       Date:  2021-05-30

Review 10.  The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer.

Authors:  Richard Cunningham; Carsten Gram Hansen
Journal:  Clin Sci (Lond)       Date:  2022-02-11       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.